within Pharmacolibrary.Drugs.ATC.C;

model C01BA71
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.8,
    Cl             = 0.058333333333333334,
    adminDuration  = 600,
    adminMass      = 0.2,
    adminCount     = 1,
    Vd             = 0.022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010833333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Quinidine is an antiarrhythmic drug used primarily for the treatment of atrial and ventricular arrhythmias. It is also known for its role as a CYP2D6 inhibitor. Combinations with psycholeptics (such as antipsychotics or tranquilizers) have been used historically for treatment-resistant psychiatric conditions involving comorbid cardiac issues, but are not widely used or approved in current practice due to safety concerns and availability of better alternatives.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for adult population receiving quinidine in combination with psycholeptics; values are based on quinidine monotherapy due to lack of published data for the combination.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01BA71;
